Clinical trial · Interventional
Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer
Phase I Study of Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT00702572CI-TRIAL-00023973terminatedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Low Enrollment
Summary
Brief summary (as posted)
The primary objective of the study is to establish the phase II recommended dose of Vorinostat when administered in combination with the regimen of carboplatin, paclitaxel and bevacizumab for patients with previously untreated advanced non-small cell lunc cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Vorinostat, Bevacizumab, Carboplatin, Paclitaxel | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- 1
- description
- Phase I dose escalating scheme
- interventionNames
- Drug: Vorinostat, Bevacizumab, Carboplatin, Paclitaxel
- type
- EXPERIMENTAL
- label
- 2
- description
- Phase 2 will evaluate the toxicities and safety profile of the 4-drug regimen.
- interventionNames
- Drug: Vorinostat, Bevacizumab, Carboplatin, Paclitaxel
Primary outcomes (1)
- measure
- Establish the phase II recommended dose (P2RD) of Vorinostat when administered in combination with the regimen of carboplatin, paclitaxel and bevacizumab for patients with previously untreated advanced non-small cell lung cancer.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Advanced non-squamous NSCLC * No prior chemotherapy for advanced disease * ECOG performance status 0 or 1 * Measurable disease * Life expectancy \> 3 months * Normal bone marrow, renal and hepatic function * Ability to take oral medications * Willingness to sign informed consent Exclusion Criteria: * History of brain metastasis * Evidence of thromboembolic phenomenon and treatment with anticoagulants * Pregnancy * Uncontrolled inter-current illness * Prior therapy with Paclitaxel
References
Publications (0)
Data not yet available
No reference posted for this study.